TheS◎Lstice

People are making a killing using solinu copytrading and you can too Here's how: 1. Sign up for solinu exchange solinu.exchange/trade?ref=SOLS… 2. Deposit USDC 3. Copytrade smart wallets 4. ???? 5. Profit You also earn points that will go towards a future airdrop

@blueyurx please

well that was pretty good! can we go higher? solana:bioJ9JTqW62MLz7UKHU69gtKhPpGi1BQhccj2kmSvUJ

The thing about wolverine is he heals and regenerates

@WifiMoneyPlant this is cope

A hot hooker a week is like $20-30k yearly Easily doable when you’re a millionaire A “wife” is much more expensive and gives less much less frequently “But but emotional support” LMAO

"I bet your little Asian fish head wife doesn't have these cannons"

@0GAntD nice nice alright then

Life will be good then you see Solstice shilling a coin you’re in and it just ruins your day

@remp0x @ovoimballin I spent 3k and sold 0 you can all eat shit fucking morons

@ovoimballin 😭 kinda surprised he could make it pump like that tho, thought he had 0 motion wolverine heals himself everyone who knows me knows i’m just a persistent mf. i keep cooking regardless. nothing has changed.

this is the current state of solana > you spend days pushing your token > ship a major feature > go enjoy the day with your family (it's fucking saturday) > it pumps from 50k to 350k while you’re gone > nukes back to where it started in a few hours with literally zero fud can anyone explain this market? the good news is wolverine always heals himself

@dezpill @ovoimballin @remp0x I didn’t farm shit fuck off

@DoctorLemma Not all heroes wear capes

If I told you a twenty-three-year-old guy once jumped into a freezing reservoir, swam ten metres down to a sunken trolleybus, kicked through a glass window in the dark, and physically pulled dozens of people out of the water, you might think it was a movie script. But it actually happened in 1976 in Yerevan, Armenia. The man was Shavarsh Karapetyan. He just happened to be jogging by the water when the bus went off the road. He also happened to be a seventeen-time world champion and eleven-time world record holder in underwater finswimming. The vehicle sank straight to the bottom with ninety-two passengers inside. Because Karapetyan was quite literally the best underwater swimmer on the planet, he spent twenty minutes diving into the raw sewage and freezing water. He would hold his breath, swim down, locate someone in the murky dark, drag them to the surface, and pass them to his brother in a rowboat before going straight back down. Twenty of those passengers survived. There is no record of a single person ever pulling off an underwater physical rescue of that scale before or since. The physical toll completely ended his athletic career. The broken glass shredded his legs, and the heavily polluted water gave him severe pneumonia and sepsis. He spent forty-five days unconscious in a hospital and lost his physical ability to compete at a world-class level. When reporters later asked him what the hardest part of the rescue was, he did not mention the cold or the injuries. He said that on one of his dives in the pitch black, he accidentally grabbed a leather seat cushion instead of a passenger, and he spent years having nightmares about the person he could have brought up instead.

This is what AI was built for

There’s always a bull market somewhere. DeSci szn

Thesis on solana:bioJ9JTqW62MLz7UKHU69gtKhPpGi1BQhccj2kmSvUJ Bio Protocol is basically what happens when you take the YC model, strip out the gatekeeping, and rebuild it on-chain for biotech. No big pharma gatekeepers. No opaque R&D pipelines but a community of patients, scientists, and researchers co-owning early-stage medicine from day one. So what is it actually? A token-governed launchpad for BioDAOs — community-owned research networks each targeting a specific disease or scientific frontier. Longevity, neurodegeneration, psychedelics, cryonics, women's health, synthetic biology. The protocol curates which DAOs get admitted, funds their initial raise, manages their secondary market liquidity, and takes a stake in every project it launches. BIO is the connective tissue holding all of it together. The business model in plain English: >6.9% equity stake in every BioDAO launched through the protocol >30% cut of a 1% fee on every secondary market trade of any launched token >BIO is the mandatory liquidity pair for all project tokens — you need BIO to trade them >Fees from BioAgent services >Every sale by any BioDAO is denominated in BIO One licensing deal, one pharma acquisition, one clinical milestone across any of 60+ pipeline projects flows value back to the protocol = structural bet. Proof of product Eli Lilly (American multinational pharmaceutical company-- one of the most conservative, credibility-heavy buyers in pharma) paid 300M for Crossbridge Bio — a drug candidate that originated inside the VitaDAO ecosystem. VitaDAO is one of the original BioDAOs running on Bio Protocol. This was the first nine-figure pharma acquisition of IP developed through tokenized, community-governed research. Pfizer is already running their BixBench benchmarking tool — 59 AI agents, 1,100+ hypotheses generated. The AI angle Bio Protocol's PeptAI agent designed a novel ADHD drug candidate targeting the OX2R receptor in roughly 24 hours. Validation cost: $1,500. Traditional pharma spends millions and takes years to reach an equivalent decision point. The agent runs a 9-gate pipeline — 8 computational gates, 1 wet lab gate — autonomously, publishes every decision on-chain via Molecule Labs, and pays for wet lab experiments directly from its own wallet. This isn't the interesting part on its own. The interesting part is what it means structurally: when discovery costs collapse from millions to thousands, a DAO treasury can now fund a candidate all the way to real lab data. That puts entire categories of neglected research within reach that pharma was never going to touch commercially. The biology behind ADHD's orexin system has been documented for years. No institution with the capital chose to develop a drug around it. A BioAgent did. The pipeline Eight BioDAOs are currently live. >VitaDAO ($8M+ funded, backed by Pfizer Ventures), >CerebrumDAO (struck a deal with Fission Pharma on neurodegeneration), >CryoDAO ($3M raised, partnered with Oxford >Cryotechnology), >ValleyDAO ($2M+, partnered with Imperial College London), >AthenaDAO (14 IP deals pending), >PsyDAO, >HairDAO, >Quantum Biology DAO. PeptAI's ignition sale on Bio Protocol is currently 10.9x oversubscribed — 546K committed against a 50K raise, with 11 days still remaining and 340M+ BioXP pledged by stakers. Three new research tokens launched recently — all oversubscribed, 40% demand increase in participation. Each one of these is a separate pipeline. Each one of these is an additional chance at a pharma exit that reprices the whole protocol. (the structural bet) The structural problems that still exist Bio Protocol has been honest about this — the two-engine thesis (community funding + agentic AI science) still leaves three unsolved problems. 1) First, data inaccessibility. The training data AI needs to reliably model drug behavior in the body sits locked inside pharmaceutical companies that spent decades collecting it and treat it as a competitive weapon. Molecule is building an open on-chain data layer to address this long-term, but it's not solved. 2) Second, wet labs. Physical validation still requires weeks of contracting and coordination. No amount of AI removes this step. PeptAI routes through Adaptyv Bio for synthesis and SPR validation — that dependency exists and adds friction. 3) Third, clinical trials. Everything DeSci has built reaches the start of the drug development path with something real in hand — a characterized compound, published binding data, permanent on-chain record of every decision. That's a fundamentally different starting point for a pharma conversation. But the clinical stage — three phases, tens to hundreds of millions in cost — is not something the current DeSci stack touches. That gap is real and acknowledged. The chart context Token is down -95%+ from the highs, up ~5X from the lowest point about a month ago. The Lilly exit happened after most of the price damage. Token is sitting near historical lows relative to what the protocol has actually demonstrated. Things to keep an eye on right now >Any licensing deal or pharma acquisition involving a BioDAO project >PeptAI candidates advancing to wet lab validation and publishing results on-chain >New BioDAO cohort launches and whether oversubscription trend continues >Molecule's Science Beach commons gaining traction as an open data layer >Whether the clinical trial gap starts getting addressed structurally TLDR (The thesis in one sentence) : a protocol that takes equity in every project it launches, mandates BIO in every trade, and has already produced one nine-figure pharma exit — sitting near all-time lows while the desci/peptide narrative is growing exponentially. Not financial advice. Do your own research. Follow for more content like this 🫡

@PaladinCavalry SEND IT OMP

$WOLVERINE bears are about to eat my fucking cock for breakfast lunch and dinner This is the most pure meme play in existence for biotech and it’s backed by the mythical meme magic of Wolverine Damage him and he regenerates, dip and it gets bought up The indomitable force

Bio + wolverine barbell iykyk

am i tweaking or does taylor swift kinda look like griffith

@watchingmarkets Oh my

Parabolic in a bear market. DeSci isn't being ignored. That's exactly how the AI run began.